{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:22:17Z","timestamp":1781112137718,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We investigated the effects of sodium\u2013glucose cotransporter 2 inhibitor (SGLT2i) administration focusing on its involvement in tubulo-interstitial disorders in diabetic kidney.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Enrolled patients with diabetic kidney disease received a mean dose of 52.3\u00a0mg of an SGLT2i (ipragliflozin) daily. Blood and urine were sampled at 0, 1, and 12\u00a0months (M).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Non-renal-dysfunction patients (NRD: baseline eGFR\u2009\u2265\u200960\u00a0mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>, <jats:italic>n<\/jats:italic>\u2009=\u200912) and renal-dysfunction patients (RD: baseline eGFR\u2009&lt;\u200960\u00a0mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>, <jats:italic>n<\/jats:italic>\u2009=\u20099) were analyzed separately. The median urine albumin-to-Cr ratio (ACR) was significantly decreased at 1\u00a0M in both groups (NRD: 163.1 at 0\u00a0M vs 118.5\u00a0mg\/g Cr at 1\u00a0M, RD: 325.2 at 0\u00a0M vs 136.0\u00a0mg\/g Cr at 1\u00a0M). In the RD, but not the NRD group, reduction of urine monocyte chemotactic protein-1 (MCP-1) by SGLT2i showed a significant difference between high-responders (HR: \u2212\u00a025.7\u2009\u00b1\u200911.4%) and low-responders (LR: 59.2\u2009\u00b1\u200917.0%), defined by ACR reduction at 1\u00a0M. Univariate analysis showed a significant correlation between the reduction of ACR and MCP-1 (<jats:italic>R<\/jats:italic>\u2009=\u20090.683, <jats:italic>p<\/jats:italic>\u2009=\u20090.042) in RD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>SGLT2i exerted an anti-albuminuric effect regardless of the presence\/absence of renal dysfunction. However, the anti-albuminuric effect of SGLT2i in patients with renal dysfunction appears more closely associated with amelioration of tubulo-interstitial disorders compared to patients without renal dysfunction.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40001-022-00737-5","type":"journal-article","created":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T10:02:32Z","timestamp":1659780152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Correlation between albuminuria and interstitial injury marker reductions associated with SGLT2 inhibitor treatment in diabetic patients with renal dysfunction"],"prefix":"10.1186","volume":"27","author":[{"given":"Saeko","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Takayanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kanozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatsugu","family":"Iwashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,6]]},"reference":[{"issue":"2","key":"737_CR1","doi-asserted-by":"publisher","first-page":"F156","DOI":"10.1152\/ajprenal.00409.2012","volume":"304","author":"V Vallon","year":"2013","unstructured":"Vallon V, Rose M, Gerasimova M, Satriano J, Platt KA, Koepsell H, et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol. 2013;304(2):F156\u201367.","journal-title":"Am J Physiol Renal Physiol"},{"key":"737_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1146\/annurev-physiol-020911-153333","volume":"74","author":"V Vallon","year":"2012","unstructured":"Vallon V, Thomson SC. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol. 2012;74:351\u201375.","journal-title":"Annu Rev Physiol"},{"issue":"3\u20134","key":"737_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000348661","volume":"122","author":"J Asakura","year":"2013","unstructured":"Asakura J, Hasegawa H, Takayanagi K, Shimazu T, Suge R, Shimizu T, et al. Renoprotective effect of pioglitazone by the prevention of glomerular hyperfiltration through the possible restoration of altered macula densa signaling in rats with type-2 diabetic nephropathy. Exp Nephrol. 2013;122(3\u20134):83\u201394.","journal-title":"Exp Nephrol"},{"issue":"5","key":"737_CR4","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1046\/j.1523-1755.1999.00721.x","volume":"56","author":"RE Gilbert","year":"1999","unstructured":"Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int. 1999;56(5):1627\u201337.","journal-title":"Kidney Int"},{"key":"737_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000325647","volume":"170","author":"SC Tang","year":"2011","unstructured":"Tang SC, Leung JC, Lai KN. Diabetic tubulopathy: an emerging entity. Contrib Nephrol. 2011;170:124\u201334.","journal-title":"Contrib Nephrol"},{"issue":"4","key":"737_CR6","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2337\/db16-0796","volume":"66","author":"RE Gilbert","year":"2017","unstructured":"Gilbert RE. Proximal tubulopathy: prime mover and key therapeutic target in diabetic kidney disease. Diabetes. 2017;66(4):791\u2013800.","journal-title":"Diabetes"},{"issue":"2","key":"737_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/dmrr.2370","volume":"29","author":"C Laustsen","year":"2013","unstructured":"Laustsen C, \u00d8stergaard JA, Lauritzen MH, N\u00f8rregaard R, Bowen S, S\u00f8gaard LV, et al. Assessment of early diabetic renal changes with hyperpolarized [1-(13) C]pyruvate. Diabetes Metab Res Rev. 2013;29(2):125\u20139.","journal-title":"Diabetes Metab Res Rev"},{"issue":"7","key":"737_CR8","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/ki.2008.350","volume":"74","author":"LG Fine","year":"2008","unstructured":"Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int. 2008;74(7):867\u201372.","journal-title":"Kidney Int"},{"issue":"10","key":"737_CR9","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","volume":"61","author":"T Rieg","year":"2018","unstructured":"Rieg T, Vallon V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia. 2018;61(10):2079\u201386.","journal-title":"Diabetologia"},{"issue":"7","key":"737_CR10","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"24","key":"737_CR11","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"4","key":"737_CR12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"5","key":"737_CR13","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587\u201397.","journal-title":"Circulation"},{"issue":"4","key":"737_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323\u201334.","journal-title":"N Engl J Med"},{"issue":"5","key":"737_CR15","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.kint.2018.04.025","volume":"94","author":"S Tanaka","year":"2018","unstructured":"Tanaka S, Sugiura Y, Saito H, Sugahara M, Higashijima Y, Yamaguchi J, et al. Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice. Kidney Int. 2018;94(5):912\u201325.","journal-title":"Kidney Int"},{"key":"737_CR16","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.biopha.2018.10.100","volume":"109","author":"MA Oraby","year":"2019","unstructured":"Oraby MA, El-Yamany MF, Safar MM, Assaf N, Ghoneim HA. Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats. Biomed Pharmacother. 2019;109:910\u201320.","journal-title":"Biomed Pharmacother"},{"key":"737_CR17","doi-asserted-by":"publisher","first-page":"4647685","DOI":"10.1155\/2016\/4647685","volume":"2016","author":"T Fiseha","year":"2016","unstructured":"Fiseha T, Tamir Z. Urinary markers of tubular injury in early diabetic nephropathy. Int J Nephrol. 2016;2016:4647685.","journal-title":"Int J Nephrol"},{"issue":"6","key":"737_CR18","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982\u201392.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"737_CR19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/dom.13101","volume":"20","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Xu L, Tian D, Xia P, Zheng H, Wang L, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(2):458\u201362.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"737_CR20","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1093\/ndt\/gfs260","volume":"27","author":"SC Tang","year":"2012","unstructured":"Tang SC, Lai KN. The pathogenic role of the renal proximal tubular cell in diabetic nephropathy. Nephrol Dial Transplant. 2012;27(8):3049\u201356.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"737_CR21","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s40620-017-0423-9","volume":"30","author":"L Zeni","year":"2017","unstructured":"Zeni L, Norden AGW, Cancarini G, Unwin RJ. A more tubulocentric view of diabetic kidney disease. J Nephrol. 2017;30(6):701\u201317.","journal-title":"J Nephrol"},{"issue":"3","key":"737_CR22","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1124\/jpet.113.203869","volume":"345","author":"N Kojima","year":"2013","unstructured":"Kojima N, Williams JM, Takahashi T, Miyata N, Roman RJ. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Ther. 2013;345(3):464\u201372.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"737_CR23","doi-asserted-by":"publisher","first-page":"e0165703","DOI":"10.1371\/journal.pone.0165703","volume":"11","author":"SJ Shin","year":"2016","unstructured":"Shin SJ, Chung S, Kim SJ, Lee EM, Yoo YH, Kim JW, et al. Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS ONE. 2016;11(11):e0165703.","journal-title":"PLoS ONE"},{"issue":"4","key":"737_CR24","doi-asserted-by":"publisher","first-page":"F767","DOI":"10.1152\/ajprenal.00565.2018","volume":"317","author":"YH Lee","year":"2019","unstructured":"Lee YH, Kim SH, Kang JM, Heo JH, Kim DJ, Park SH, et al. Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy. Am J Physiol Renal Physiol. 2019;317(4):F767\u201380.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"12","key":"737_CR25","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s00210-018-1544-y","volume":"391","author":"NAT Abbas","year":"2018","unstructured":"Abbas NAT, El Salem A, Awad MM. Empagliflozin, SGLT2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expression. Naunyn Schmiedebergs Arch Pharmacol. 2018;391(12):1347\u201360.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"3","key":"737_CR26","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.kint.2018.05.002","volume":"94","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Nakano D, Guan Y, Hitomi H, Uemura A, Masaki T, et al. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int. 2018;94(3):524\u201335.","journal-title":"Kidney Int"},{"issue":"1","key":"737_CR27","doi-asserted-by":"publisher","first-page":"e87857","DOI":"10.1371\/journal.pone.0087857","volume":"9","author":"R Tofik","year":"2014","unstructured":"Tofik R, Ohlsson S, Bakoush O. Urinary concentration of monocyte chemoattractant protein-1 in idiopathic glomerulonephritis: a long-term follow-up study. PLoS ONE. 2014;9(1):e87857.","journal-title":"PLoS ONE"},{"issue":"6","key":"737_CR28","doi-asserted-by":"publisher","first-page":"e100777","DOI":"10.1371\/journal.pone.0100777","volume":"9","author":"N Terami","year":"2014","unstructured":"Terami N, Ogawa D, Tachibana H, Hatanaka T, Wada J, Nakatsuka A, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice. PLoS ONE. 2014;9(6):e100777.","journal-title":"PLoS ONE"},{"issue":"3","key":"737_CR29","first-page":"191","volume":"48","author":"Y Ishibashi","year":"2016","unstructured":"Ishibashi Y, Matsui T, Yamagishi S. Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation. Horm Metab Res. 2016;48(3):191\u20135.","journal-title":"Horm Metab Res"},{"issue":"11","key":"737_CR30","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1038\/nm.3363","volume":"19","author":"K Hasegawa","year":"2013","unstructured":"Hasegawa K, Wakino S, Simic P, Sakamaki Y, Minakuchi H, Fujimura K, et al. Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat Med. 2013;19(11):1496\u2013504.","journal-title":"Nat Med"},{"issue":"2","key":"737_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2174\/1573402112666160302102217","volume":"12","author":"K Hasegawa","year":"2016","unstructured":"Hasegawa K, Wakino S, Sakamaki Y, Muraoka H, Umino H, Minakuchi H, et al. Communication from tubular epithelial cells to podocytes through sirt1 and nicotinic acid metabolism. Curr Hypertens Rev. 2016;12(2):95\u2013104.","journal-title":"Curr Hypertens Rev"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00737-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-022-00737-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00737-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T10:07:02Z","timestamp":1659780422000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-022-00737-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,6]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["737"],"URL":"https:\/\/doi.org\/10.1186\/s40001-022-00737-5","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,6]]},"assertion":[{"value":"10 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee at which the studies were conducted (Saitama Medical Center, Saitama Medical University Ethics Committee; IRB Approval Number 2470) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written and oral informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interest exists.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}